Loss-of-function mutations in ndh do not confer delamanid, ethionamide, isoniazid, or pretomanid resistance in Mycobacterium tuberculosis
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.01096-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Sushil Pandey und 13 weiteren Autor:innen. Beteiligte Einrichtung: Queensland Mycobacterium Reference Laboratory, Pathology Queensland , Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Tuberculosis, Multidrug-Resistant. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institute of Health Grant, Programme d'Investissements d'Avenir "Mustart".
Abstract (Originalsprache)
Results from clinical strains and knockouts of the H37Rv and CDC1551 laboratory strains demonstrated that ndh ( Rv1854c ) is not a resistance-conferring gene for isoniazid, ethionamide, delamanid, or pretomanid in Mycobacterium tuberculosis . This difference in the susceptibility to NAD-adduct-forming drugs compared with other mycobacteria may be driven by differences in the absolute intrabacterial NADH concentration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Queensland Mycobacterium Reference Laboratory, Pathology Queensland , Brisbane, Queensland, Australia.
- Department of Microbiology and Immunology, Albert Einstein College of Medicine , Bronx, New York, USA.
- Public Health Agency of Sweden , Solna, Sweden.
- Emerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute , Milan, Italy.
- Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR9017 - CIIL - Center for Infection and Immunity of Lille , Lille, France.
- Department of Infectious Diseases, Linköping University Hospital , Linköping, Sweden.
ORCID-Profile: Sushil Pandey, Catherine Vilchèze, Jim Werngren, Arnold Bainomugisa, Mikael Mansjö, Ramona Groenheit, Paolo Miotto, Daniela M Cirillo, Christopher Coulter, Alain R Baulard, William R Jacobs, Kamel Djaout, Claudio U Köser
Förderung
- NIAID NIH HHS
- National Institute of Health Grant
- Programme d'Investissements d'Avenir "Mustart"
Zitieren
APA
Pandey, S., Vilchèze, C., Werngren, J., Bainomugisa, A., Mansjö, M., Groenheit, R., Miotto, P., Cirillo, D. M., Coulter, C., Baulard, A. R., Schön, T., Jacobs, W. R., Djaout, K., & Köser, C. U. (2024). Loss-of-function mutations in ndh do not confer delamanid, ethionamide, isoniazid, or pretomanid resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01096-23
Vancouver
Pandey S, Vilchèze C, Werngren J, Bainomugisa A, Mansjö M, Groenheit R, et al. Loss-of-function mutations in ndh do not confer delamanid, ethionamide, isoniazid, or pretomanid resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01096-23
BibTeX
@article{Pandey2024,
author = {Pandey, Sushil and Vilchèze, Catherine and Werngren, Jim and Bainomugisa, Arnold and Mansjö, Mikael and Groenheit, Ramona and Miotto, Paolo and Cirillo, Daniela M and Coulter, Christopher and Baulard, Alain R and Schön, Thomas and Jacobs, William R and Djaout, Kamel and Köser, Claudio U},
title = {Loss-of-function mutations in ndh do not confer delamanid, ethionamide, isoniazid, or pretomanid resistance in Mycobacterium tuberculosis},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.01096-23}
}
EUVIMED